| P50 | author | Georgina V. Long | Q42947998 |
| | Pablo Fernandez-Peñas | Q54286183 |
| P2093 | author name string | Rachael Anforth | |
| P2860 | cites work | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 |
| | Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 |
| | NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 |
| | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 |
| | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 |
| | Targeting cancer with small molecule kinase inhibitors | Q29547395 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 |
| | Improving melanoma classification by integrating genetic and morphologic features | Q33340639 |
| | Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 |
| | Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1 | Q82567338 |
| | Activation of Akt by mechanical stretching in human epidermal keratinocytes | Q83185491 |
| | Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma | Q83195713 |
| | Ultraviolet A and photosensitivity during vemurafenib therapy | Q83378765 |
| | Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib | Q84292261 |
| | Vemurafenib in melanoma with BRAF V600E mutation | Q85087769 |
| | A phase II trial of sorafenib in metastatic melanoma with tissue correlates | Q33785790 |
| | RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors | Q35721081 |
| | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 |
| | Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma | Q36679188 |
| | Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study | Q36816946 |
| | Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition | Q36822126 |
| | RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 |
| | Dermatologic symptoms associated with the multikinase inhibitor sorafenib | Q37333134 |
| | Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases | Q37480713 |
| | BRAF as therapeutic target in melanoma | Q37720832 |
| | British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology | Q37737765 |
| | Meta-analysis of dermatological toxicities associated with sorafenib | Q37867169 |
| | Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib | Q37930711 |
| | Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma | Q38026916 |
| | Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib | Q38494010 |
| | BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency | Q39649761 |
| | The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations | Q39803993 |
| | Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. | Q39874679 |
| | Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 |
| | BRAF targeted therapy changes the treatment paradigm in melanoma | Q42733647 |
| | Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer | Q43299267 |
| | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 |
| | Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. | Q45930106 |
| | Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Q46006772 |
| | Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene | Q46200338 |
| | A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel | Q46448115 |
| | Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib | Q46542862 |
| | Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy | Q46857527 |
| | Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. | Q50518821 |
| | Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. | Q53178811 |
| | First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | Q54499836 |
| | Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901. | Q54500306 |
| | Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. | Q54502379 |
| | Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 |
| | Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma | Q58024726 |
| | Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) | Q58024747 |
| | Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma | Q59626442 |
| P433 | issue | 1 | |
| P921 | main subject | dabrafenib | Q3011604 |
| P304 | page(s) | e11-8 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Cutaneous toxicities of RAF inhibitors | |
| P478 | volume | 14 | |